Drugs / LNF1901
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06226363 | Feb 2024 → Feb 2025 overdue | cancer | Shandong New Time Pharmaceutical Co., LTD | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LNF1901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06226363 ↗ |
| Modality | Monoclonal antibody | “LNF1901 Monoclonal Antibody Injection” NCT06226363 ↗ |